Sydney Thib

Feb 1, 2024 | jrheum.org | Chandra Farrer |Sydney Thib |Lihi Eder |Dana Jerome

Key Indexing Terms: biologics quality improvement wait time Delays in initiation of advanced therapy, which includes biologics and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), contribute to poor patient outcomes.1 Early initiation of treatment for inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis, has been shown to improve patient outcomes and delay disease progression.2-5 Based on this knowledge, a...

Nov 24, 2023 | jrheum.org | Chandra Farrer |Sydney Thib |Lihi Eder |Dana Jerome

Use of Coordinator Role Improves Access to Rheumatologic Advanced Therapy Chandra Farrer, Sydney Thib, Lihi Eder, Dana Jerome, Natasha Gakhal The Journal of Rheumatology Nov 2023, jrheum.2023-0402; DOI: 10.3899/jrheum.2023-0402

Oct 24, 2023 | jrheum.org | Chandra Farrer |Lihi Eder |Dana Jerome |Sydney Thib

Use of Coordinator role improves access to Rheumatologic Advanced Therapy Chandra Farrer, Sydney Thib, Lihi Eder, Dana Jerome, Natasha Gakhal The Journal of Rheumatology Nov 2023, jrheum.2023-0402; DOI: 10.3899/jrheum.2023-0402